英文  登录 | 注册 | 服务热线:0512 - 63172736
产品展示
您现在所在的位置: 首页 > 产品展示
COVID-19 Spike Variants Panel
COVID-19, resulting from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)infection, is an unprecedented public health emergency which has directly caused hundreds of thousandsof deaths around the world and put health systems under immense pressure and stretched them beyondtheir capacity. In recent months, massive immunization with newly developed COVID-19 vaccines hasshown promising results towards curbing the spread of COVID-19. However, variants identified indifferent regions have sparked concerns about a potentially diminished vaccine efficacy against thesevariants.Through collaboration with a consortium of academic advisers and our internal scientific intelligence,we have been monitoring the emergence of different SARS-Cov-2 variants worldwide. Consequently,we have generated a library of constructs encoding spike proteins of SARS-CoV-2 carrying definedmutations of projected biological significance, including but not limited to: the UK strain (B.1.1.7),South Africa strain (B.1.351), Brazil strain (P.1) and California strain (Cal.20C). These mutants havebeen further subcloned into expression vectors for two versions of the SRAS-CoV-2 spike protein:• Full-length pre-fusion SARS-CoV-2 spike glycoprotein (S-2P)• RBD-Fc fusion protein of SARS-CoV-2 spike glycoproteinIn addition, our engineered expression vectors contain a variety of tags, facilitating the production oftagged recombinant proteins for research and product development.During the current Stage II of the COVID-19 pandemic during which vaccines have shown promisingresults in containment of the virus spread, we anticipate our COVID-19 Spike Variants Panel willgreatly accelerate research and development in the following areas:• For the characterization of immune reactivities of sera from vaccinated individuals againstvariants;• To be used as probes for isolating and cloning of variant-specific human monoclonal antibodiesfrom infected individuals for development of new therapeutic antibodies;• To be used to generate immune profiles to stratify populations that may require additionalvaccination with variant-specific vaccines;• To be used for the development of surrogate in vitro neutralizing assays based on RBD-ACE2binding;• To further facilitate our understanding between the SARS-CoV-2 spike protein structure andantibody response, for the development of future vaccines with a broader-spectrum of antibodyresponse.At Immune Tech, it is our mission to engage our full capacity, knowledge base, and enthusiasm in oureffort to help combat the novel coronavirus pandemic. We look forward to your comments, suggestions,and collaboration.
2021年季节性流感病毒相关产品
简述整理中。。。
产品推荐——益泰生物助力布尼亚病毒检测产品的研发
简述整理中。。。
2019-SARS-CoV-2 (2019-nCoV)
严重急性呼吸道综合征冠状病毒2型(英语:Severe Acute Respiratory Syndrome Coronavirus 2,缩写:SARS-CoV-2)[2][3]是冠状病毒科乙型冠状病毒属严重急性呼吸道综合征相关冠状病毒种的一个分型,具有包膜的正链单股RNA,它造成了于2019年底爆发的2019冠状病毒病(COVID-19)。它的基因序列和非典病毒及中东呼吸综合征病毒属于同一谱系但不同进化枝。
2020年季节性流感病毒相关产品
IMMUNE TECH提供以下2020年季节性流感HA蛋白
2018-2019年季节流感病毒产品
2018-2019年北半球季节流感疫苗病毒株
流感病毒NA系列产品
流感神经氨酸酶是在流感病毒表面发现的一种神经氨酸酶
E6 (HPV-18)
Applications:WB standard, antibody ELISA, immunogen, etc
MB (Ureaplasma urealyticum)
Applications:WB standard, antibody ELISA, immunogen, etc.
MOMP (C. trachomatis strain 404 Serovar L3)
Applications:WB standard, antibody ELISA, immunogen, etc.
Capsid (Porcine circovirus 2)
Applications: WB standard, antibody ELISA, immunogen, etc.
N (HP-PRRSV)
Applications: WB standard, antibody ELISA, immunogen, etc.
Capsid (Zika/Brazil)
Applications: WB, ELISA, IP, IF etc.
首页 上一页 1 下一页 最后一页
首页 | 产品展示 | 定制服务 | 自主技术平台 | 资料下载 | 新闻资讯 | FAQ | 关于我们 | 联系方式
Copyright © 2016 益泰(苏州)生物技术有限公司 All Rights Reserved.
抗体定制  病毒蛋白  细菌蛋白  传染病  HIV抗体  流感抗体
苏ICP备16002008号
  • 公司致力于病毒和肿瘤领域生物药物
  • 与临床诊断试剂盒的研发和生产以及相关领域抗体、重组蛋白、试剂盒系列产品的开发和生产